These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. J Rheumatol; 1998 Nov; 25(11):2140-5. PubMed ID: 9818656 [Abstract] [Full Text] [Related]
14. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. Salvarani C, Boiardi L, Macchioni P, Rossi F, Tartoni P, Casadei Maldini M, Mancini R, Beltrandi E, Portioli I. Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440 [Abstract] [Full Text] [Related]
18. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica. Braun N, Fritz P, Rieth A, Schroth W, Kimmel M, Biegger D, Zakim D, Alscher MD. J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157 [Abstract] [Full Text] [Related]
19. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management. Gonzalez-Gay MA, Garcia-Porrua C, Miranda-Filloy JA, Martin J. Drugs Aging; 2006 Oct; 23(8):627-49. PubMed ID: 16964987 [Abstract] [Full Text] [Related]
20. Current understanding and management of giant cell arteritis and polymyalgia rheumatica. Ghosh P, Borg FA, Dasgupta B. Expert Rev Clin Immunol; 2010 Nov; 6(6):913-28. PubMed ID: 20979556 [Abstract] [Full Text] [Related] Page: [Next] [New Search]